OCX: Koefisien rega marang pendapatan OncoCyte Corp.

Logo korporat perusahaan OncoCyte Corp (OCX)

The commercialization of OncoCyte Corporation (OCX) molecular tests is in its early stages, which creates significant pressure on costs. Comparing the price-to-sales ratio on GURU.Markets, we see that the metric is fixed at 24.00. OncoCyte Corporation (OCX) focuses on liquid biopsy for monitoring recurrences and transplants. The business possesses exceptional macro-resilience, as cancer diagnostics are independent of economic cycles and seasonality.

OncoCyte Corp. (OCX): Rasio rega marang pendapatan saka 04.07.2022 nganti 18.06.2025

Rincian analitis perusahaan OncoCyte Corp. (OCX)

- rega lan prakiraan konsensus rega:
Bagan bursa oncocyte.com|OCX - Prakiraan konsensus analis
- informasi kapitalisasi pasar:
Kapitalisasi pasar OncoCyte Corp.|OCX - Nilai Total Perusahaan
- rincian nilai buku perusahaan:
Aset Bersih saben Saham OncoCyte|OCX - Nilai Buku Perusahaan|Koefisien Nilai Pasar marang Nilai Buku oncocyte.com|OCX - Aset Agregat Perusahaan
- indikator beban kredit lan likuiditas emiten:
Rasio Utang marang Ekuitas OncoCyte Corporation|OCX - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas OncoCyte Inc|OCX - Utang perusahaan|Utang-utang marang nilai buku OncoCyte Corp.|OCX - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan OncoCyte|Likuiditas darurat oncocyte.com
- data bathi resik lan rasio valuasi:
OCX - Penghasilan resik|Bathi resik mangsa ngarep OncoCyte Corporation|OCX - Pangali P/E|Rasio prakiraan rega marang bathi OncoCyte Corp|OCX - Pangali rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan OncoCyte Corp.|OCX - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan OncoCyte|OCX - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan oncocyte.com|OCX - Wutah bathi saben saham ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep OncoCyte Corporation
- data total pendapatan lan volume dodolan:
OCX - Pendapatan perusahaan|Pendapatan sing dikarepake perusahaan oncocyte.com|OCX - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep OncoCyte Corp.
Analisis fundamental perusahaan:OCX - oncocyte.com
Produk sing diprodhuksi OncoCyte Corporation

Stable demand for early cancer diagnostics makes the OncoCyte Corporation (OCX) business resilient to macroeconomic shocks. The relationship between market capitalization and sales volume, represented by the price-to-sales ratio, measures the premium the market is willing to pay for future revenue growth, allowing investors to identify overinflated expectations or asset undervaluation before official financial reports are published.

Perusahaan pesaing

Koefisien rega marang pendapatan carislifesciences.com|Multiplikator P/S GH (Guardant Health)|Koefisien rega marang pendapatan Veracyte Inc (VCYT)|CELC - Rasio rega marang pendapatan|Koefisien rega marang pendapatan GRAIL Bio GRAL|Myriad Genetics, Inc. (MYGN) - Rasio rega marang pendapatan|Rega marang dodolan castlebiosciences.com (CSTL)|Rasio rega marang pendapatan Burning Rock|Rasio kapitalisasi marang pendapatan VNRX (VolitionRx Ltd)|Multiplikator P/S BDSX|Kapitalisasi marang pendapatan Precipio Inc PRPO|Rasio rega marang pendapatan Check-Cap CHEK|Mainz Biomed NV (MYNZ) - Rega marang dodolan